



Development Grants 2020 Peer Review Guidelines

Opening date:	23 October 2019
Closing date and time:	17.00 AEDT on 11 December 2019
Commonwealth policy entity:	National Health and Medical Research Council (NHMRC)
Sapphire assistance and enquiries:	NHMRC Research Help Centre Phone: 1800 500 983 (+61 2 6217 9451 for international callers) Email: sapphire.helpdesk@nhmrc.gov.au Note: The Sapphire Help Desk aims to provide a reply to all requests for general assistance within two working days. This timeframe may be delayed during peak periods or for more detailed requests for assistance.
Development Grants enquiries:	Phone: 1800 500 983 (+61 2 6217 9451 for international callers) Email: development.grants@nhmrc.gov.au

1	INTRODUCTION	4
2	KEY CHANGES.....	4
3	PRINCIPLES, CONDUCT AND OBLIGATIONS DURING PEER REVIEW	4
3.1	NHMRC’s Principles of Peer Review	4
3.2	The Australian Code for the Responsible Conduct of Research.....	5
3.3	Disclosures of Interest.....	5
3.3.1	What is an interest?.....	5
3.3.2	What is a Conflict of Interest (CoI)?	6
3.3.3	Disclosure of Interests in the Peer Review Process.....	6
3.3.4	Failure to disclose an interest	7
3.4	Freedom of Information (FoI).....	7
3.5	Complaints.....	7
4	DEVELOPMENT GRANTS PEER REVIEW PROCESS.....	8
4.1	Overview of the Development Grants peer review process.....	8
4.2	Roles and responsibilities.....	9
4.3	Reviewing Development Grant applications	12
4.3.1	Identification of applications with an Aboriginal and Torres Strait Islander health focus....	12
4.3.2	Receipt and initial processing of applications	12
4.3.3	Disclosure of interests and peer reviewer suitability.....	12
4.3.4	Assignment of applications to peer reviewers	12
4.3.5	Briefing.....	13
4.3.6	Assessment of applications.....	13
4.3.6.1	Relative to opportunity and career disruption	13
4.3.6.2	Industry-relevant experience	13
4.3.6.3	Use of Impact Factors and other metrics	13
4.3.6.4	Enhancing reproducibility and applicability of research outcomes.....	14
4.3.6.5	Research Integrity Issues	14
4.3.6.6	Contact between peer reviewers and applicants	14
4.3.7	Principles for setting conditions of funding for NHMRC grants	14
4.3.8	Funding Recommendation.....	15
4.3.9	Notification of Outcomes	15
	Appendix A - Understanding the Principles of Peer Review.....	16
	Appendix B - Guidance for Declaring and Assessing Disclosures of Interest.....	18
	Appendix C – Development Grants Assessment Criteria	23
	Appendix D – Development Grants Category Descriptors.....	24
	Appendix E - Indigenous Research Excellence Criteria	31
	Appendix F – Guidance for assessing applications against the Indigenous Research Excellence Criteria.....	32

Appendix G – NHMRC Relative to Opportunity and Career Disruption Policy.....33
Appendix H – Guide to Evaluating Industry-Relevant Experience.....35

1 INTRODUCTION

The National Health and Medical Research Council (NHMRC) is responsible for managing the Australian Government's investment in health and medical research in a manner consistent with Commonwealth legislation, guidelines and policies. NHMRC has a responsibility to ensure taxpayers' funds are invested appropriately to support the best health and medical research. Expert peer review assists us in fulfilling this responsibility.

This guide outlines the overarching principles and obligations under which the Development Grants peer review process operates, including:

- obligations in accordance with legislation, guidelines and policies
- how to declare and manage conflicts of interest, and
- standards and best practice for the conduct of peer review.

This guide should be read in conjunction with the:

- *Development Grants 2020 Grant Guidelines* which set out the rules, objectives and other considerations relevant to NHMRC funding.
- [Policy on the Disclosure of Interests requirements for prospective and appointed NHMRC committee members](#) (Section 39 Committees). This Policy outlines peer reviewers' responsibilities in order to ensure all disclosures of interests are addressed in a rigorous and transparent way throughout the period of a peer reviewer's participation in NHMRC Committees.

2 KEY CHANGES

Applicants should note the following significant changes for the Development Grants 2020 peer review:

- Two additional reviewers (one scientific and one commercial) per application, therefore each application will be reviewed by up to 10 (5 scientific and 5 commercial) peer reviewers.
- Qualitative feedback will be provided to applicants.
- Grant Review Panel (GRP) meetings will no longer be held to discuss applications by exception.
- Peer reviewers will be able to seek clarification on peer review policies and processes during the assessment phase from an independent Chair.

3 PRINCIPLES, CONDUCT AND OBLIGATIONS DURING PEER REVIEW

The peer review process requires all applications to be reviewed by individuals with appropriate expertise. This carries an obligation on the part of peer reviewers to act in good faith, in the best interests of NHMRC and the research community and in accordance with NHMRC policies (outlined below).

3.1 NHMRC's Principles of Peer Review

NHMRC's Principles of Peer Review (the Principles) are high-level, guiding statements that underpin all NHMRC's peer review processes, and include:

- **Fairness.** Peer review processes are fair and seen to be fair by all.
- **Transparency.** Applies to all stages of peer review.
- **Independence.** Peer reviewers provide independent advice. There is also independent oversight of peer review processes by independent Chairs and Observers.
- **Appropriateness and balance.** There is appropriate experience, expertise and representation of peer reviewers assessing applications.
- **Research community participation.** Persons holding taxpayer-funded grants should willingly make themselves available to participate in peer review processes, whenever possible, in accordance with the obligations in the Funding Agreement.
- **Confidentiality.** Participants respect that confidentiality is important to the fairness and robustness of peer review.
- **Impartiality.** Peer review is objective and impartial, with appropriate processes in place to manage disclosures of interest.
- **Quality and excellence.** NHMRC will continue to introduce evidence-based improvements into its processes to achieve the highest quality decision-making through peer review.

Additional details underpinning the Principles can be found at [Appendix A](#).

3.2 The Australian Code for the Responsible Conduct of Research

The [Australian Code for the Responsible Conduct of Research](#) (the Code) requires researchers participating in peer review do so in a way that is ‘fair, rigorous and timely and maintains the confidentiality of the content’.

The Code is supported by additional supplementary guidance, including [Peer Review: A guide supporting the Australian Code for the Responsible Conduct of Research](#).

3.3 Disclosures of Interest

3.3.1 What is an interest?

NHMRC is committed to ensuring that interests¹ of any kind are dealt with consistently, transparently and with rigour, in accordance with Part 5, section 42A of the *National Health and Medical Research Council Act 1992* (NHMRC Act) and sections 16A and 16B of the *Public Governance, Performance and Accountability Rule 2014*² (made under the subsection 29(2) of the *Public Governance, Performance and Accountability Rule 2013* (PGPA Act)).

In particular, under:

- subsection 42A(3) of the NHMRC Act, peer reviewers of Council and Committees must “give to the CEO a written statement of any interest the peer reviewer has that may relate to the activity of the Council or Committee” before starting to hold office. “Interest” is defined in section 4 of the

¹ An “Interest” is defined in section 4 of the NHMRC Act as meaning “any direct or indirect, pecuniary or non-pecuniary, interest”. Under section 29 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act), “an official ... who has a material personal interest that relates to the affairs of the entity must disclose details of the interest”.

² Made under subsection 29(2) of the PGPA Act.

NHMRC Act as meaning “any direct or indirect, pecuniary or non-pecuniary interest.”

- section 29 of the PGPA Act, “an official... who has a material personal interest that relates to the affairs of the entity must disclose details of the interest”. This obligation (unlike the obligation in subsection 42A(3) of the NHMRC Act) is ongoing and not limited to a particular point in time.

For the purposes of this document, the terms “material personal interest” and “interest” are regarded as interchangeable, and whilst the term “interest/s” has been used for ease of reading, this policy includes guidance on each.

Although many positives may emerge from collaborations and partnerships with industry, there is potential for conflicts of interest to arise. These conflicts may arise from competing commitments and Financial Interests that may, or may be perceived to affect scientific endeavours.

3.3.1 What is a Conflict of Interest (CoI)?

A CoI exists when there is a divergence between professional responsibilities (as a peer reviewer) and personal interests. Such conflicts have the potential to lead to biased advice affecting objectivity and impartiality. By managing any conflict, NHMRC maintains the integrity in its processes in the assessment of scientific and technical merit of the application.

For NHMRC peer review purposes, interests may fall into the broad domains of:

- Involvement with the application under review
- Working relationships
- Professional relationships and associations
- Social relationships or associations
- Collaborations
- Teaching or supervisory relationships
- Financial relationships or interests
- Other relevant interests or relationships

For further information peer reviewers should consult the NHMRC [*Policy on the Disclosure of Interests Requirements for Prospective and Appointed NHMRC Committee Members*](#) (Section 39 Committees).

Researchers frequently have a CoI that cannot be avoided. Decision making processes in research often need expert advice, and the pool of experts in a field can be so small that all the experts have some link with the matter under consideration. An individual researcher should therefore expect to be conflicted from time to time, be ready to acknowledge the conflict and make disclosures as appropriate.

An outline of potential CoI situations and guidance is provided for peer reviewers at [Appendix B](#).

3.3.2 Disclosure of Interests in the Peer Review Process

Peer reviewers must identify and disclose interests they may have with any of the Chief Investigators (CIs) and Associate Investigators (AIs) on applications they will be reviewing. After appointment as a peer reviewer, but before assessing any applications, peer reviewers are required to disclose their interests in writing. While disclosures of interest must be declared at the beginning of the peer review process, new or previously unrecognised disclosures of interest must be declared at any stage of the peer review process. Declarations must include details that substantiate when collaborations occurred (i.e. month and year). NHMRC will use these details to verify and determine the level of conflict. Any peer reviewer who has an interest that is determined by NHMRC to have a ‘high’ CoI will not be able to participate in the review of that application. However, they can provide scientific advice at the request of the Chair.

3.3.3 Failure to disclose an interest

A failure to disclose an interest without a reasonable excuse will result in the termination of the peer reviewer's appointment under section 44B of the NHMRC Act (section 44B also covers failure to comply with section 29 of the PGPA Act).

It is important for peer reviewers to inform NHMRC of any circumstances which may constitute an interest, at any point during the peer review process. Accordingly, peer reviewers are encouraged to consult the Secretariat if they are uncertain about any disclosure of interest matter.

3.4 Freedom of Information (Fol)


NHMRC is subject to the *Freedom of Information Act 1982* which provides a statutory right for an individual to seek access to documents. If documents that deal with peer review fall within the scope of a request, the FOI process includes consultation and exemptions. NHMRC endeavours to protect the identity of peer reviewers assigned to a particular application.

3.5 Complaints

NHMRC deals with any complaints, objections and requests for clarification on the peer review process. NHMRC may contact peer reviewers and/or Chairs involved to obtain additional information on particular application/s. Further information about the NHMRC complaints process can be found on the [NHMRC website](#).

4 DEVELOPMENT GRANTS PEER REVIEW PROCESS

4.1 Overview of the Development Grants peer review process



*Dates are indicative

Date	Activity
11 December 2019	Deadline for Development Grant 2020 application submission
Dec 2019 – Jan 2020	Application eligibility review and confirmation
Mar 2020	Peer reviewers disclose interests and suitability against applications
Feb – Mar 2020	Indigenous assessments obtained
Mar – Apr 2020	Allocation of applications to peer review
Apr – May 2020	Peer reviewers review applications and submit scores and written assessments against Development Grants assessment criteria for each allocated application
June - July 2020	Notification of outcomes

*Dates are indicative and subject to change.

Further information on the steps outlined in this process is provided in section 4.3 *Reviewing Development Grant applications*.

4.2 Roles and responsibilities

The roles and responsibilities of those participating in the **Development Grants** peer review process are identified in the table below.

Development Grants Peer Review Participants Table

Roles	Responsibilities
Chair	<p>The Chair's role is to ensure NHMRC's procedures are adhered to and that fair and equitable consideration is given to every application being reviewed by peer reviewers.</p> <p>Chairs do not assess applications, however they must manage the process of peer review in accordance with this Guide. Chairs may raise issues of a general nature for advice or action as appropriate with NHMRC staff.</p> <p>Chairs need to:</p> <ul style="list-style-type: none"> • familiarise themselves with this document and other material as identified by NHMRC staff • identify and advise NHMRC of all interests they have with Development Grant applications. • ensure NHMRC procedures are followed • record and notify NHMRC of any requests for clarification or advice. • assist peer reviewers with their duties and in understanding what is expected of them, including: <ul style="list-style-type: none"> ○ promoting good engagement by peer reviewers in all assessments ○ guiding peer reviewers when they consider 'relative to opportunity', including career disruptions ○ advising peer reviewers that assessments should lead to an outcome where the applications are appropriately considered against the Development Grants assessment criteria and associated category descriptors (Appendix C and D). ○ guiding peer reviewers when they consider the assessment against the <i>Indigenous Research Excellence Criteria</i> for applications with an Aboriginal and Torres Strait Islander health focus <p>Chairs may need to:</p> <ul style="list-style-type: none"> • review assessor application statement summaries for inappropriate, biased or defamatory comments.

<p>Peer reviewers: Scientific or Commercialisation</p>	<p>Peer reviewers need to:</p> <ul style="list-style-type: none"> • familiarise themselves with this Guide and other material as identified by NHMRC staff • identify and advise NHMRC of all interests they have with applications assigned to them • if assessing as a Scientific peer reviewer, provide a fair and impartial assessment against the Development Grants Scientific Merit of the Proposal assessment criterion and associated category descriptors (Appendix C and D) for each non-conflicted application assigned, in a timely manner • if assessing as a Commercialisation peer reviewer, provide a fair and impartial assessment against both the Development Grants Record of Commercial Achievements and Commercial Potential assessment criteria and associated category descriptors (Appendix C and D) for each non-conflicted application assigned, in a timely manner • assess track record by taking into consideration research achievements ‘relative to opportunity’, including any career disruptions, where applicable • consider the assessment against the <i>Indigenous Research Excellence Criteria</i> (Appendix E and F) provided for applications with an Aboriginal and Torres Strait Islander focus • write a summary of their assessment of each application assigned to them.
<p>Lead Scientific Peer Reviewer</p>	<p>The Lead Scientific Peer Reviewer needs to:</p> <ul style="list-style-type: none"> • familiarise themselves with this Guide and other material as identified by NHMRC staff • identify and advise NHMRC of all interests they have with applications assigned to them • provide a fair and impartial assessment against the Development Grants Scientific Merit of the Proposal assessment criterion and associated category descriptors (Appendix C and D) for each non-conflicted application assigned, in a timely manner • assess track record by taking into consideration research achievements ‘relative to opportunity’, including any career disruptions, where applicable • consider the assessment against the <i>Indigenous Research Excellence Criteria</i> (Appendix E and F) provided for applications with an Aboriginal and Torres Strait Islander focus • rigorously assess the proposed budget to ensure that Personnel Support Packages (PSPs), Direct Research Costs (DRCs) and equipment requests are appropriate for the project and fully justified • prepare a recommendation for the Lead Commercialisation Peer Reviewer to either: leave the requested budget intact, support proposed modifications to the budget, propose further modifications to the budget, or seek advice from the Chair regarding specific budget requests. • write a summary of their assessment of each application assigned to them.
<p>Lead Commercialisation Peer Reviewer</p>	<p>The Lead Commercialisation Peer Reviewer needs to:</p> <ul style="list-style-type: none"> • familiarise themselves with this Guide and other material as identified by NHMRC staff • identify and advise NHMRC of all interests they have with applications assigned to them • provide a fair and impartial assessment against the Development Grants Record of Commercial Achievements and Commercial Potential assessment criteria and

	<p>associated category descriptors (Appendix C and D) for each non-conflicted application assigned, in a timely manner</p> <ul style="list-style-type: none"> • assess track record by taking into consideration research achievements ‘relative to opportunity’, including any career disruptions, where applicable • consider the assessment against the <i>Indigenous Research Excellence Criteria</i> (Appendix E and F) provided for applications with an Aboriginal and Torres Strait Islander focus • support the Lead Scientific Peer Reviewer with the review of the requested budget as required with reference to the individual elements of the budget ensuring PSPs, DRCs and equipment requests are appropriate for the project and fully justified. • write a summary of their assessment of each application assigned to them.
Senior NHMRC Staff	<p>NHMRC staff with appropriate expertise may be involved in:</p> <ul style="list-style-type: none"> • reviewing allocation of applications to peer reviewers • assisting and advising on the peer review process.
NHMRC Staff	<p>Under direction from the CEO, NHMRC staff will be responsible for overall administration of the peer review process and for the conduct of specific activities.</p> <p>NHMRC staff will:</p> <ul style="list-style-type: none"> • invite individuals to participate as peer reviewers or as a Chair • determine whether disclosed interests pose a conflict and the level of that conflict. • act as the first point of contact for peer reviewers • provide briefings to peer reviewers • determine eligibility of applications • assign applications to peer reviewers, • support the operation of NHMRC’s granting system • assist the Chair in responding to peer reviewer enquiries • ensure that all peer reviewers are provided with the necessary information to review each application • seek feedback from the Chair and peer reviewers on improvements for future processes.
Indigenous health research peer reviewers	<p>Indigenous health research peer reviewers will review how well each application addresses NHMRC’s <i>Indigenous Research Excellence Criteria</i> (Appendix E and F).</p> <p>Indigenous health research external assessors will not participate in scoring. They will act as external experts and provide guiding comments to the peer reviewers relating to the <i>Indigenous Research Excellence Criteria</i>.</p>
Community Observers	<p>NHMRC invites respected members of the general community to observe whether NHMRC policy and procedures are being adhered to during the peer review process. Observers assist NHMRC in ensuring that the assessment of all applications is fair, equitable and impartial.</p> <p>Observers will be briefed on the processes and procedures for the peer review of Development Grant applications. They will not participate in the review of any application.</p> <p>Observers will:</p> <ul style="list-style-type: none"> • identify and advise NHMRC of all conflict of interests • observe the procedural aspects of peer review

	<ul style="list-style-type: none"> • provide feedback to NHMRC on the consistency of peer review processes and policies. <p>Observers may raise issues of a general nature for advice or action as appropriate with NHMRC staff.</p> <p>Observers are subject to the same disclosure of interest requirements as peer reviewers. Where a high CoI exists, the observer will not observe the review of the respective application(s).</p>
--	---

4.3 Reviewing Development Grant applications

All **Development Grant** applications are assessed against the **Development Grants Assessment Criteria** and the associated *Category Descriptors* at Appendix C and D. Applications that are accepted by NHMRC as relating to the improvement of Aboriginal and Torres Strait Islander health (see section 4.3.1) are also assessed against the *Indigenous Research Excellence Criteria* as set out at Appendix E and F.

4.3.1 Identification of applications with an Aboriginal and Torres Strait Islander health focus

Applications relating specifically to Aboriginal and Torres Strait Islander people’s health will be identified by information provided in the application. Researchers with Aboriginal and Torres Strait Islander health expertise will check whether these applications have at least 20% of their research effort and/or capacity building focused on Aboriginal and Torres Strait Islander health.

For applications confirmed as relating specifically to Aboriginal and Torres Strait Islander health research, NHMRC will endeavour to obtain at least one assessment against the *Indigenous Research Excellence Criteria* (Appendix E) from a peer reviewer with expertise in Aboriginal and Torres Strait Islander health. For further information on assessing applications that have a focus on the health of Indigenous Australians, see Guidance for Assessing applications against the *Indigenous Research Excellence Criteria* at Appendix F.

4.3.2 Receipt and initial processing of applications

NHMRC staff will verify that Development Grant applications meet eligibility criteria. Applicants will be advised if their application is ineligible. However, in some instances these applications will remain in the peer review process until their ineligibility is confirmed. Eligibility rulings may be made at any point in the peer review process.

4.3.3 Disclosure of interests and peer reviewer suitability

Peer reviewers will be provided with an overview of applications and will need to disclose their interests in accordance with the guidelines provided at *Section 3.3* and Appendix B.

Some peer reviewers may have a disclosure of interest for which they require a decision. For these, NHMRC will assess the information provided by the peer reviewer and specify a level of peer review participation for the peer reviewer.

Peer reviewers are also required to select their level of suitability for applications, based on the information available to them in the application summary.

Taking into account potential CoIs and suitability, peer reviewers will be assigned to applications.

4.3.4 Assignment of applications to peer reviewers

Taking into account CoIs and peer reviewer suitability, NHMRC staff will assign applications and peer

reviewers. It is expected each peer reviewer will be assigned approximately 10 applications. However this is subject to change, depending on the number and peer review area of applications. Each application will be assigned up to five scientific and five commercialisation reviews.

4.3.5 Briefing

NHMRC will provide briefing material that will provide peer reviewers further details on their duties and responsibilities associated with the Development Grants peer review process. This will be made available to peer reviewers prior to assessing applications. Further information may be provided as necessary throughout the peer review process.

4.3.6 Assessment of applications

Peer reviewers will be given access to applications (where no high COI exists). Peer reviewers will assess all applications assigned to them against the assessment criteria, and allocate scores, using the category descriptors, taking into account career disruptions and other 'relative to opportunity' considerations (Appendix G), where applicable.

Peer reviewers will be able to seek clarification from an independent Chair on peer review policies and processes during the assessment phase. Peer reviewers are not to discuss applications with other peer reviewers before scoring an application. This is to ensure peer reviewers provide independent scores. Peer reviewers are required to provide a brief summary of their assessment for each application they assess, summarising the strengths and weaknesses of the application. This feedback will be provided to the applicant. Peer reviewers must remember their obligation to remain fair and impartial when providing their feedback to applicants.

Peer reviewers must ensure scores and application summaries are completed by the nominated due date. If peer reviewers are unable to meet this requirement, they must contact NHMRC promptly to discuss alternative arrangements.

Peer reviewers' scores will be used to create ranked lists from which funding recommendations will be based.

4.3.6.1 Relative to opportunity and career disruption

Panel members must take into account productivity relative to opportunity and, where applicable, career disruption considerations in the assessment of all applications. This reflects NHMRC's policy that assessment processes should accurately assess an applicant's track record and associated productivity relative to stage of career, including consideration as to whether productivity and contribution are commensurate with the opportunities available to the applicant. To assist peer reviewers with their assessment, further details regarding relative to opportunity and career disruptions are provided at [Appendix G](#).

4.3.6.2 Industry-relevant experience

Peer reviewers are to recognise an applicant's industry-relevant experience and outputs. To assist peer reviewers with their assessment, the *Guide to Evaluating Industry-Relevant Experience* is provided at [Appendix H](#).

4.3.6.3 Use of Impact Factors and other metrics

Peer reviewers are to take into account their expert knowledge of their field of research, as well as the citation and publication practices of that field, when assessing the publication component of an applicant's track record. Track record assessment takes into account the overall impact, quality and contribution to the field of the published journal articles from the grant applicant, not just the standing of the journal in which those articles are published.

It is not appropriate to use publication metrics such as Journal Impact Factors.

The [San Francisco Declaration on Research Assessment](#) (DoRA) makes recommendations for improving the evaluation of research assessment. NHMRC is a signatory to DoRA and adheres to the recommendations outlined in DoRA for its peer review processes.

4.3.6.4 Enhancing reproducibility and applicability of research outcomes

Peer reviewers are required to consider the general strengths and weaknesses of the experimental design of the proposal to ensure robust and unbiased results. Assessment of the experimental design should include consideration of the following, as appropriate:

- scientific premise of the proposed research (i.e. how rigorous were previous experimental designs that form the basis for this proposal)
- techniques to be used
- details for appropriate blinding (during allocation, assessment and analysis)
- strategies for randomisation
- details and justification for control groups
- effect size and power calculations to determine the number of samples/subjects in the study (where appropriate)
- consideration of relevant experimental variables, and
- sex and gender elements of the research to maximise impact and any other considerations relevant to the field of research necessary to assess the rigour of the proposed design.

4.3.6.5 Research Integrity Issues

The peer review process can sometimes identify possible research integrity issues with applicants (e.g. concerns about possible plagiarism, inconsistencies in the presentation of data, inaccuracies in the presentation of track record information) or the behaviour of other peer reviewers. NHMRC has established specific processes for addressing research integrity concerns that arise in peer review. Peer reviewers must not discuss their concerns with other peer reviewers as this may jeopardise the fair assessment of an application. Instead, these issues should be raised with NHMRC separately from the peer review process. Advice about how to raise concerns and a description of how this process is managed is provided on the [NHMRC website](#).

Applications that are the subject of a research misconduct allegation will continue to progress through NHMRC peer review processes while any investigations are ongoing. NHMRC liaises with the institution regarding the outcome of any investigation and, if necessary, will take action under the *NHMRC Research Integrity and Misconduct Policy* available on the [NHMRC website](#).

4.3.6.6 Contact between peer reviewers and applicants

Peer reviewers must not contact applicants about their application under review. If this occurs, the peer reviewer may be removed from the process, and there is the potential for exclusion from future NHMRC peer review.

Where an applicant contacts a peer reviewer, the relevant application may be excluded from consideration.

In either case, contact between applicants and peer reviewers may raise concerns about research integrity and NHMRC may refer such concerns to the relevant Administering Institution.

4.3.7 Principles for setting conditions of funding for NHMRC grants

Setting a condition of funding (CoF) on a grant through the peer review process is, and should be, a rare event. When this does occur, peer reviewers will use the principles set out below to decide the CoF. These principles aim to achieve a consistent approach, minimise the number of conditions set and

ensure conditions are unambiguous and able to be assessed.

CoFs relate to the awarding of funding, the continuation of funding or the level of funding. They do not relate to conditions which affect either eligibility to apply or subsequent peer review.

The principles are:

- NHMRC seeks to minimise the administrative burden on researchers and Administering Institutions.
- CoFs must not relate to the competitiveness of an application (e.g. project requires more community engagement); these issues should be considered during peer review and be reflected in the scores for the application.
- Any CoFs must be clear and measurable, so that the condition can be readily assessed as having been met.

4.3.8 Funding Recommendation

After the panel meeting/s, application scores from all peer reviewers are used to create a ranked list. This final ranked list will be used to prepare funding recommendations to NHMRC's Research Committee and Council for advice to the CEO, who will then make recommendations to the Minister for Health.

4.3.9 Notification of Outcomes

Applicants will be notified of the outcomes via NHMRC's granting system and their Administering Institution's Research Administration Officer.

Appendix A - Understanding the Principles of Peer Review

Fairness

- Peer review processes are designed to ensure that peer review is fair and seen to be fair by all involved.
- Peer reviewers have an obligation to ensure that each application is judged consistently and objectively on its own merits, against published assessment criteria. Peer reviewers must not introduce irrelevant issues into the assessment of an application.
- Applications will be subject to scrutiny and evaluation by individuals who have appropriate knowledge of the fields covered in the application.
- Peer reviewers should ensure that their assessments are accurate and that all statements are capable of being verified.
- Complaints processes are outlined on the [NHMRC website](#). All complaints to NHMRC relating to the peer review process are dealt with independently and impartially.

Transparency

- NHMRC will publish key dates, all relevant material for applicants and peer reviewers, and grant announcements on its website and/or via [GrantConnect](#).
- NHMRC publicly recognises the contribution of participants in the peer review process, through publishing their names on the NHMRC website.³

Independence

- The order of merit determined by peer review panels is not altered by NHMRC. However, additional applications may be funded ‘below the funding line’ in priority or strategic areas.
- Panel Chairs are independent and are not involved in the peer review of any application before that panel. Chairs act to ensure that NHMRC’s processes are followed for each scheme, including adherence to the principles of this Guide.

Appropriateness and balance

- Peer reviewers are selected to meet the program’s objectives and to ensure adequate expertise to assess the applications received.
- NHMRC endeavours to ensure that panels are constituted with an appropriate representation of gender, geography and large and small institutions.

Confidentiality

- NHMRC provides a process by which applications are considered by peer reviewers in-confidence. In addition NHMRC is bound by the provisions of the Privacy Act 1988 in relation to

³ Such information will be in a form that prevents applicants determining which particular experts were involved in the review of their application.

its collections and use of personal information, and by the commercial confidentiality requirements under section 80 of the NHMRC Act.

- Peer reviewers are to treat applications in-confidence and must not disclose any matter regarding applications under review to people who are not part of the process.
- Any information or documents made available to peer reviewers in the peer review process are confidential and must not be used other than to fulfil their role.
- NHMRC is subject to the *Freedom of Information Act 1982* which provides a statutory right for an individual to seek access to documents. If documents that deal with peer review fall within the scope of a request, there is a process for consultation and there are exemptions from release. NHMRC will endeavour to protect the identity of peer reviewers assigned to a particular application.

Impartiality

- Peer reviewers must disclose all interests and matters that may, or may be perceived to, affect objectivity in considering particular applications.
- Panel members must disclose relationships with other members of the panel, or with grants being reviewed by other panel members, including:
 - research collaborations
 - student, teacher or mentoring relationships
 - employment arrangements
 - any other relationship that may, or may be seen to, undermine fair and impartial judgement.
- Disclosures of interest are managed to ensure that no one with a high conflict is involved in decision making on relevant applications.

Quality and Excellence

- NHMRC will continue to introduce evidence-based improvements into its peer review processes.
- Any significant change will be developed in consultation with the research community and may involve piloting new processes.
- NHMRC will strive to introduce new technologies that are demonstrated to maximise the benefits of peer review and improve the efficiency and effectiveness of the process while minimising individual workloads.
- NHMRC will undertake post-program assessment of all its schemes with feedback from the sector.
- NHMRC will provide advice, training and feedback for peer reviewers new to NHMRC peer review.
- Where NHMRC finds peer reviewers to be substandard in their performance, NHMRC may provide such feedback directly to the peer reviewer or their institution.

Appendix B - Guidance for Declaring and Assessing Disclosures of Interest

Conflicts frequently are regarded as a positive indicator that peer reviewers are recognised leaders who:

- have expert advice or skills
- have been given professional opportunities
- have received government funding, and
- are supported by the companies working to raise the standard of individual and public health throughout Australia.

A disclosure of interest does not mean that a peer reviewer has engaged in an inappropriate activity. It is a collaboration which may, or could be perceived to, impact impartial peer review and thus needs to be disclosed and transparently managed (where necessary) to safeguard the integrity of the peer review process. It is the peer reviewer's responsibility to disclose all interests. Failure to do so without a reasonable excuse may result in the peer reviewer being removed from the panel in accordance with subsection 44B(3) of the NHMRC Act.

In determining if an interest is a conflict, peer reviewers should give consideration to the following values that underpin the robust nature of peer review:

- **Excellence through expert peer review:** The benefits of peer reviewers' expert advice need to be balanced with the risk of real and or perceived interests affecting an impartial review.
- **Significance:** Not all interests are equal. The type of interest needs to be considered in terms of its significance and time when it occurred.
- **Integrity through disclosure:** Peer review rests on the integrity of peer reviewers to disclose any interests and contribute to transparently managing any real or perceived conflicts in a rigorous way. The peer review system cannot be effective without trusting peer reviewers' integrity.

In determining if an interest is a 'High', 'Low', or 'No' CoI, the responsibility is on the peer reviewer to consider the specific circumstances of the situation. This includes:

- the interest's significance
- its impact on the impartiality of the reviewer, and
- maintaining the integrity of the peer review process.

Once a peer reviewer discloses a conflict they can detail a brief explanation of the disclosure of interest in NHMRC's granting system to enable accurate clarification for decisions. Wherever possible, peer reviewers are encouraged to provide sufficient detail in the explanation such as date (month and year) of collaborations. Disclosures of interest where appropriate are to be documented for conflicts with both CIs and AIs.

The written declaration of interest is retained for auditing purposes by NHMRC. The details below provide generalist examples but are not to be regarded as a prescriptive checklist.

HIGH Interest

Situation		Example
Associated with Application and/or Chief Investigator (CI)	✓	Peer reviewer is a CI or AI on the application under review.
	✓	Peer reviewer has had discussions/significant input into the study design or research proposal of this application.
Collaborations	✓	Peer reviewer has collaborated, in a significant way, on publications within the last three calendar years (co-authorship), pending current-round applications, existing NHMRC or other grants.
	✓	There is a direct association/collaboration between the peer reviewer and a member of the CI team that may have, or may be perceived to have, a vested interest in this research.
Working relationships	✓	Peer reviewer has the same employer, is part of the same organisation, or is negotiating for employment at the applicant's institution, including: <ul style="list-style-type: none"> • in the same research field at an independent Medical Research Institute. • in the same Department or School of a university. • in the same Department of a hospital.
	✓	Peer reviewer is in a position of influence within an organisation, or with a pecuniary interest, e.g. Dean of Faculty or School/Institute Directors.
	✓	Peer reviewer would benefit if the proposal was successful as an associate of the same scientific advisory committee, review board, exam board, trial committee, Data and Safety Monitoring Board etc. For example, a board of the hospital in which the research would be conducted.
Professional relationships and interests	✓	Peer reviewer's organisation is affiliated or associated with organisations that may have, or may be perceived to have, vested interest in the research. For example, a pharmaceutical company has provided drugs for testing and therefore has a vested interest in the outcome.
Social relationship and / or interests	✓	The peer reviewer has a known personal/social/perceived relationship with a CI on the application.
Teaching or supervisory relationship	✓	Peer reviewer has taught or supervised the applicant for either undergraduate or postgraduate studies, co-supervised a CI, within the last three years.
Direct financial interest in the application	✓	Peer reviewer has the potential for financial gains if the application is successful, such as, benefits from: payments from resulting patents, supply of goods and services, access to facilities, and provision of cells/animals as part

		of the collaboration.
	✓	Peer reviewer receives research funding or other support from a company and the research proposal may involve collaboration/association with relevant company.
Other interests or situations	✓	Peer reviewer has had an ongoing scientific disagreement and/or dispute with the applicant/s. This may still be ruled high if the events in question occurred beyond the last three years.
	✓	The peer reviewer feels that there are other interests or situations not covered above that could influence/or be perceived to influence, the peer review process

LOW Interest

Situation		Example
Collaborations	✓	Peer reviewer and a CI on the application have collaborated more than three years ago.
	✓	Within the last three years the peer reviewer has published with the CI as part of a multi-author collaborative team (i.e. ≥ 10) where the peer reviewer did not have a major professional interactive role (i.e. the peer reviewer's role was a leadership role).
	✓	A co-worker is planning future collaborations with a CI.
	✓	Peer reviewer and a named AI on the application are actively or have previously collaborated within the last three years.
	✓	Without financial gain or exchange, a peer reviewer and a contributor of the research team have shared cells/animals/reagents/specialist expertise (biostatistician) etc. but have no other connection to each other.
	✓	Collaboration between a CI and the peer reviewer's research group.
	✓	Peer reviewer is considering/planning/or has planned a future collaboration with a CI on the application but have no current collaborations or joint applications.
Working relationships	✓	Peer reviewer has the same employer, is part of the same organisation or is negotiating employment at the applicant's institution
	✓	Peer reviewer and a CI work: <ul style="list-style-type: none"> at the same institution and do not know each other. in the same Faculty or College of a university but in different Schools or Departments and do not know each other. in the same organisation, but the peer reviewer or applicant holds an honorary appointment.
	✓	Peer reviewer and a CI work for two organisations that are affiliated but there is/are no direct association/collaboration.
	✓	Peer reviewer and a CI are on the same scientific advisory committee, review board, exam board, trial committee, Data and Safety Monitoring Board etc., but otherwise have no association that would constitute a High decision.
Professional relationships and interests	✓	Peer reviewer's organisation is affiliated with the CI's organisation.
	✓	Where two organisations are affiliated but there is no direct association/collaboration between the CI and peer reviewer and there is no other link that would constitute a 'High' decision.
	✓	When the peer reviewer's institution has an indirect affiliation/association with the organisation(s) that may have, or may be perceived to have, a vested interest in this research. For example, peer reviewer is employed at a large institution that does not have a direct research interest/association with the organisation(s) in question.
Social relationship	✓	Peer reviewer's partner or an immediate family member have a known personal/social (non-work)/perceived relationship with a CI on the

and / or interests		application, but the peer reviewer themselves does not have any link with the CI that would be perceived or constitute a ‘High’ decision.
Teaching or supervisory relationship	✓	Peer reviewer taught or supervised the applicant for either undergraduate or postgraduate studies, co-supervised a CI, or the peer reviewer’s research was supervised by a CI, more than three years ago.
Financial interest in the application	✓	Peer reviewer has an associated patent pending; supplied goods and services, improved access to facilities, or provided cells/animals etc. to a named CI for either undergraduate or postgraduate studies.
	✓	Peer reviewer has intellectual property that is being commercialised by an affiliated institution. Peer reviewer has previously provided and/or received cells/animals to/from a CI on the application, but has no other financial interests directly relating to this application that would constitute a ‘High’ decision.
	✓	Peer reviewer receives research funding or other support from a company, and the research proposal may impact upon the company.
Other interests or situations	✓	Peer reviewer may, or may be perceived to be, biased in their review of the application. For example, peer reviewer is a lobbyist on a particular issue.

Appendix C – Development Grants Assessment Criteria

Applications for Development Grants 2020 are assessed by peers on the extent to which they address the assessment criteria:

- Scientific Merit of the Proposal (fitness for purpose of the science and quality of the scientific research team) – 40%
- Record of Commercial Achievements – 20%
- Commercial Potential – 40%

Applications will be assessed against the category descriptors at [Appendix D](#).

Applications are assessed relative to opportunity, taking into consideration any career disruptions, where applicable (see Appendix G).

It is recognised that Aboriginal and/or Torres Strait Islander applicants often make additional valuable contributions to policy development, clinical/public health leadership and/or service delivery, community activities and linkages, and are often representatives on key committees. If applicable, these contributions will be considered when assessing research output and track record.

Appendix D – Development Grants Category Descriptors

Category	Scientific Peer Reviewers only	Commercialisation Peer Reviewers only	
	Scientific Merit of the Proposal (Fitness for purpose of the science and quality of the scientific research team) 40%	Record of Commercial Achievements (relative to opportunity) 20%	Commercial Potential 40%
7 Outstanding by International Standards	<p>The research plan:</p> <ul style="list-style-type: none"> ▪ is well-defined, highly coherent and strongly developed ▪ will successfully achieve proof-of-concept ▪ is a near flawless design ▪ is without question highly feasible and thus almost certain to be successfully completed ▪ is consistent with the objectives of the Development Grant scheme. <p>The scientific research team:</p> <ul style="list-style-type: none"> ▪ has, overall, an outstanding record of research achievements in the field of the proposed research ▪ brings together all of the expertise needed for success. 	<p>Relative to opportunity, the research team:</p> <ul style="list-style-type: none"> ▪ has proven successful national and international involvement ▪ in commercialisation of research including for example, granted patents, industry consultation, licensing of IP ▪ has had direct involvement in industry placements and/or involvement with establishing spin off companies ▪ has a record of commercial achievements which is outstanding by international standards ▪ is highly likely to achieve a very significant commercial outcome. 	<p>The commercial proposal:</p> <ul style="list-style-type: none"> ▪ is linked to a human health issue where the size and/or impact for the potential market is extremely large ▪ provides a clear description of a highly feasible commercial/development pathway should the product, process or technology prove successful ▪ will be conducted in an environment with excellent institutional commercial advice and development support structures such as a commercialisation office or equivalent, which will increase the likelihood of arriving at a commercial outcome within a foreseeable timeframe ▪ clearly outlines how the proposed research meets the scheme objectives. <p>The product, process or technology:</p> <ul style="list-style-type: none"> ▪ is unique or provides an internationally competitive edge ▪ is linked to a very strong IP position. <p>Funding the project:</p> <ul style="list-style-type: none"> ▪ would significantly increase the probability of successful commercialisation, usually by adding substantial value to the concept and/or supporting a critical proof of concept and/or creation of a commercialisable prototype that will enrich the Australian life sciences industry sector and bring economic benefit to Australia.

Category	Scientific Peer Reviewers only	Commercialisation Peer Reviewers only	
	Scientific Merit of the Proposal (Fitness for purpose of the science and quality of the scientific research team) 40%	Record of Commercial Achievements (relative to opportunity) 20%	Commercial Potential 40%
6 Excellent	<p>The research plan:</p> <ul style="list-style-type: none"> ▪ is clearly defined, coherent and well developed ▪ is very well designed ▪ is feasible and highly likely to be successfully completed ▪ will successfully achieve proof-of-concept ▪ is consistent with the objectives of the Development Grant scheme. <p>The scientific research team:</p> <ul style="list-style-type: none"> ▪ the leader has an excellent record of research achievements, as do, on average, the other team members in the field of the proposed research ▪ brings together all of the expertise needed for success. 	<p>Relative to opportunity, the research team:</p> <ul style="list-style-type: none"> • has significant experience in national and international commercialisation of research including approved patents, industry consultation, licensing of IP, and has had direct involvement with industry • has a record of commercial achievements which is of a high international standard • is very likely to achieve a significant commercial outcome. 	<p>The commercial proposal:</p> <ul style="list-style-type: none"> • is linked to a human health issue where the size and/or impact for the potential market is very large • provides a clear description of a feasible commercial/development pathway should the product, process or technology prove to be successful • will be conducted in an environment with strong institutional commercial advice and development support structures, including an institutional commercialisation office or equivalent which will support the likelihood of arriving at a commercial outcome within a foreseeable timeframe • clearly outlines how the proposed research meets all the scheme objectives. <p>The product, process or technology:</p> <ul style="list-style-type: none"> • is internationally competitive and likely to be attractive to a commercial partner • could be linked to a strong IP position. <p>Funding the project:</p> <ul style="list-style-type: none"> • would increase the probability of successful commercialisation, usually by adding substantial value to the concept and/or supporting a critical proof of concept and/or creation of a commercialisable prototype that will bring economic benefit to Australia.

Category	Scientific Peer Reviewers only	Commercialisation Peer Reviewers only	
	Scientific Merit of the Proposal (Fitness for purpose of the science and quality of the scientific research team) 40%	Record of Commercial Achievements (relative to opportunity) 20%	Commercial Potential 40%
5 Very Good	<p>The research plan:</p> <ul style="list-style-type: none"> • is generally clear in its scientific plan and is logical • raises only a few minor concerns with respect to the study design • will likely be successfully completed and achieve proof-of-concept • is consistent with the objectives of the Development Grant scheme. <p>The scientific research team:</p> <ul style="list-style-type: none"> • members on average, have good record of research achievements in the field of the proposed research • possesses most of the expertise needed for success. 	<p>Relative to opportunity, the research team:</p> <ul style="list-style-type: none"> • has been involved in national commercialisation of research including approved patents, industry consultation, licensing of intellectual property, and has had involvement in industry • has a record of commercial achievements which is of a high or growing national standard • has the ability to promote a strong commercial outcome. 	<p>The commercial proposal:</p> <ul style="list-style-type: none"> • is linked to a human health issue where the size and/or impact for the potential market is large • provides an outline of a feasible commercial development pathway should the product, process or technology prove to be successful • will be conducted in an environment with good access to institutional commercial development advice and support structures which will mostly likely support the likelihood of arriving at a commercial outcome within a foreseeable timeframe • adequately outlines how the proposed research meets the scheme objectives. <p>The product, process or technology:</p> <ul style="list-style-type: none"> • has significant commercial potential nationally and potentially, internationally • could be linked to a strong or strongly developing IP position. <p>Funding the project:</p> <ul style="list-style-type: none"> • would most likely bring economic benefit to Australia.

Category	Scientific Peer Reviewers only	Commercialisation Peer Reviewers only	
	Scientific Merit of the Proposal (Fitness for purpose of the science and quality of the scientific research team) 40%	Record of Commercial Achievements (relative to opportunity) 20%	Commercial Potential 40%
4 Good	<p>The research plan:</p> <ul style="list-style-type: none"> • is good in terms of its objectives • contains several areas of weakness in the experimental design and feasibility • raises several concerns about successful completion • may successfully achieve proof-of-concept • is consistent with the objectives of the Development Grant scheme. <p>The scientific research team:</p> <ul style="list-style-type: none"> • members on average, have good record of research achievements in the field of the proposed research • possesses much of the expertise needed for success. 	<p>Relative to opportunity, the research team:</p> <ul style="list-style-type: none"> • has a solid record of national research commercialisation achievement including approved patents, industry consultation and licensing of IP • has a record of commercial achievements which is of a good national standard • has some potential to promote a viable commercial outcome. 	<p>The commercial proposal:</p> <ul style="list-style-type: none"> • is linked to a human health issue where the size and/or impact for the potential market is moderate. • provides an outline of a commercialisation pathway which could be better developed and raised only a few minor concerns. • will be conducted in an environment with access to commercial development advice and support structures, which could support the likelihood of arriving at a commercial outcome within a foreseeable timeframe • outlines how the proposed research meets the scheme objectives. <p>The product, process or technology:</p> <ul style="list-style-type: none"> • has some commercial potential nationally, but is very limited at an international level • could be linked to a developing IP position. <p>Funding the project:</p> <ul style="list-style-type: none"> • may bring economic benefit to Australia.

Category	Scientific Peer Reviewers only	Commercialisation Peer Reviewers only	
	Scientific Merit of the Proposal (Fitness for purpose of the science and quality of the scientific research team) 40%	Record of Commercial Achievements (relative to opportunity) 20%	Commercial Potential 40%
3 Marginal	<p>The research plan:</p> <ul style="list-style-type: none"> • is clearly described, but may not be successful • contains several study design problems or flaws that will limit the successful completion of the study • will not significantly advance current knowledge in the field • is not likely to achieve proof-of-concept • may not be consistent with the objectives of the Development Grant scheme. <p>The scientific research team:</p> <ul style="list-style-type: none"> • has no expertise in most areas required for project success. 	<p>Relative to opportunity, the research team:</p> <ul style="list-style-type: none"> • has limited record of research commercialisation achievements including approved patents, industry consultation, licensing of IP • does not have any significant record of commercial achievements • has a limited ability to promote a viable commercial outcome. 	<p>The commercial proposal:</p> <ul style="list-style-type: none"> • is linked to a human health issue where the size and/or impact for the potential market is limited • provides a description of a pathway to commercialisation that raises several concerns • will be conducted in an environment with limited access to institutional commercial development advice and support structures, which is unlikely to support the likelihood of arriving at a commercial outcome within a foreseeable timeframe • may not meet the scheme objectives. <p>The product, process or technology:</p> <ul style="list-style-type: none"> • has limited commercial potential • could be linked to a weak IP position. <p>Funding the project:</p> <ul style="list-style-type: none"> • will not bring economic benefit to Australia.

Category	Scientific Peer Reviewers only	Commercialisation Peer Reviewers only	
	Scientific Merit of the Proposal (Fitness for purpose of the science and quality of the scientific research team) 40%	Record of Commercial Achievements (relative to opportunity) 20%	Commercial Potential 40%
2 Unsatisfactory	<p>The research plan:</p> <ul style="list-style-type: none"> • has poorly described or underdeveloped objectives • contains multiple major study design problems or flaws that will limit or prohibit the successful completion of the study • is not likely to advance current knowledge in the field • will not likely achieve proof-of-concept • may not be consistent with the objectives of the Development Grant scheme. <p>The scientific research team:</p> <ul style="list-style-type: none"> • has no expertise in most areas required for project success. 	<p>Relative to opportunity, the research team:</p> <ul style="list-style-type: none"> • has little record of research commercialisation achievements including approved patents, industry consultation, licensing of IP • does not have any significant record of commercial achievements • has a very little potential to promote a viable commercial outcome. 	<p>The commercial proposal:</p> <ul style="list-style-type: none"> • is linked to a human health issue where the size and/or impact for the potential market is small • does not contain a clear description of a pathway to commercialisation • will not be conducted in an environment supportive of commercial development • may not meet the scheme objectives. <p>The product, process or technology:</p> <ul style="list-style-type: none"> • has no commercial potential • could be linked to a very weak IP position. <p>Funding the project:</p> <ul style="list-style-type: none"> • will not bring economic benefit to Australia.

Category	Scientific Peer Reviewers only	Commercialisation Peer Reviewers only	
	Scientific Merit of the Proposal (Fitness for purpose of the science and quality of the scientific research team) 40%	Record of Commercial Achievements (relative to opportunity) 20%	Commercial Potential 40%
1 Poor	<p>The research plan:</p> <ul style="list-style-type: none"> • has poorly described or under developed objectives • contains multiple major study design problems or flaws that will limit or prohibit the successful completion of the study • will not advance current knowledge in the field • will not achieve proof of concept • may not be consistent with the objectives of the Development Grant scheme. <p>The scientific research team:</p> <ul style="list-style-type: none"> • has no expertise in most areas required for project success. 	<p>Relative to opportunity, the research team:</p> <ul style="list-style-type: none"> • has no record of research commercialisation achievements including approved patents, industry consultation, licensing of IP • does not have any significant record of commercial achievements • has no ability to promote a viable commercial outcome. 	<p>The commercial proposal:</p> <ul style="list-style-type: none"> • is linked to a human health issue where the size and/or impact for the potential market is too small for probable commercial viability • does not contain a clear description of a pathway to commercialisation • will not be conducted in an environment supportive of commercial development • does not meet the scheme objectives. <p>The product, process or technology:</p> <ul style="list-style-type: none"> • has no commercial potential • has a non-viable IP position. <p>Funding the project:</p> <ul style="list-style-type: none"> • would not increase the interest of commercial partners • will not bring economic benefit to Australia.

Appendix E - Indigenous Research Excellence Criteria

To qualify as Aboriginal and Torres Strait Islander health research, at least 20% of the research effort and/or capacity building must relate to Aboriginal and Torres Strait Islander health.

Qualifying applications must address the NHMRC Indigenous Research Excellence Criteria as follows:

- Community engagement - the proposal demonstrates how the research and potential outcomes are a priority for Aboriginal and Torres Strait Islander communities with relevant community engagement by individuals, communities and/or organisations in conceptualisation, development and approval, data collection and management, analysis, report writing and dissemination of results.
- Benefit - the potential health benefit of the project is demonstrated by addressing an important public health issue for Aboriginal and Torres Strait Islander people. This benefit can have a single focus or affect several areas, such as knowledge, finance and policy or quality of life. The benefit may be direct and immediate, or it can be indirect, gradual and considered.
- Sustainability and transferability - the proposal demonstrates how the results of the project have the potential to lead to achievable and effective contributions to health gain for Aboriginal and Torres Strait Islander people, beyond the life of the project. This may be through sustainability in the project setting and/or transferability to other settings such as evidence based practice and/or policy. In considering this issue, the proposal should address the relationship between costs and benefits.
- Building capability - the proposal demonstrates how Aboriginal and Torres Strait Islander people, communities and researchers will develop relevant capabilities through partnerships and participation in the project.

Appendix F – Guidance for assessing applications against the Indigenous Research Excellence Criteria

Peer reviewers should consider the following when assessing applications that have a focus on the health of Indigenous Australians. The points below should be explicit throughout the application and not just addressed separately within the Indigenous criteria section.

Community Engagement

- Does the proposal clearly demonstrate a thorough and culturally appropriate level of engagement with the Aboriginal and Torres Strait Islander community or health services prior to submission of the application?
- Is there clear evidence that the level of engagement throughout the project will ensure the feasibility of the proposed study?
- Has the application demonstrated evidence that any of the methods, objectives or key elements of the proposed work have been formed, influenced or defined by the community?
- Were the Indigenous community instrumental in identifying and inviting further research into the health issue and will the research outcomes directly benefit the ‘named’ communities?
- Is there a history of working together with the ‘named’ communities e.g. co-development of the grant, involvement in pilot studies or how the ‘named’ communities will have input/control over the research process and outcomes across the life of the project?

Benefit

- Does the proposal clearly outline the potential health benefits (both intermediate and long term, direct and indirect) to Aboriginal and Torres Strait Islander people?
- Does the proposal demonstrate that the benefit(s) of the project have been determined or guided by Aboriginal and Torres Strait Islander people, communities or organisations themselves?

Sustainability and Transferability

- Does the proposal:
 - Provide a convincing argument that the outcomes will have a positive impact on the health of Aboriginal and Torres Strait Islander peoples, which can be maintained after the study has been completed?
 - Have relevance to other Indigenous communities?
 - Clearly plan for and articulate a clear approach to knowledge translation and exchange?
 - Demonstrate that the findings are likely to be taken up in health services and/or policy?
- Will the outcomes from the study make a lasting contribution to Aboriginal and Torres Strait Islander communities and their wellbeing?

Building Capability

- Does the proposal outline how Aboriginal and Torres Strait Islander people and/or communities will benefit from capability development?
- Does the proposal outline how researchers and individuals/groups associated with the research project will develop capabilities that allow them to have a greater understanding/engagement of Aboriginal and Torres Strait Islander peoples?

Appendix G – NHMRC Relative to Opportunity and Career Disruption Policy

Purpose

The purpose of this document is to outline NHMRC's Relative to Opportunity Policy with respect to peer review and eligibility to apply for Emerging Leadership Investigator Grants.

NHMRC's objective is to support the best Australian health and medical research and the best researchers, at all career stages. NHMRC seeks to ensure that researchers with a variety of career experiences and those who have experienced pregnancy or a major illness/injury or have caring responsibilities, are not disadvantaged in applying for NHMRC grants.

Policy approach

NHMRC considers Relative to Opportunity to mean that assessment processes should accurately assess an applicant's track record and associated productivity relative to stage of career, including considering whether productivity and contribution are commensurate with the opportunities available to the applicant. It also means that applicants with career disruptions should not be disadvantaged (in terms of years since they received their PhD) when determining their eligibility for Emerging Leadership Investigator Grants and that their Career Disruptions should be considered when their applications are being peer reviewed.

In alignment with *NHMRC's Principles of Peer Review*, particularly the principles of fairness and transparency, the following additional principles further support this objective:

- **Research opportunity:** Researchers' outputs and outcomes should reflect their opportunities to advance their career and the research they conduct.
- **Fair access:** Researchers should have access to funding support available through NHMRC grant programs consistent with their experience and career stage.
- **Career diversity:** Researchers with career paths that include time spent outside of academia should not be disadvantaged. NHMRC recognises that time spent in sectors such as industry, may enhance research outcomes for both individuals and teams.

The above principles frame NHMRC's approach to the assessment of a researcher's track record during expert review of grant applications and eligibility of applicants applying for Emerging Leadership Investigator Grants. NHMRC expects that those who provide expert assessment during peer review will give clear and explicit attention to these principles to identify the highest quality research and researchers to be funded. NHMRC recognises that life circumstances can be very varied and therefore it is not possible to implement a formulaic approach to applying Relative to Opportunity and Career Disruption considerations during peer review.

Relative to Opportunity considerations during peer review of applications for funding

During peer review of applications, circumstances considered under the Relative to Opportunity Policy are:

- amount of time spent as an active researcher
- available resources, including situations where research is being conducted in remote or isolated communities

- building relationships of trust with Aboriginal and Torres Strait Islander communities over long periods that can impact on track record and productivity
- clinical, administrative or teaching workload
- relocation of an applicant and his/her research laboratory or clinical practice setting or other similar circumstances that impact on research productivity
- for Aboriginal and/or Torres Strait Islander applicants, community obligations including ‘sorry business’
- the typical performance of researchers in the research field in question
- research outputs and productivity noting time employed in other sectors. For example there might be a reduction in publications when employed in sectors such as industry
- carer responsibilities (that do not come under the Career Disruption policy below).

Appendix H – Guide to Evaluating Industry-Relevant Experience

Principles

NHMRC is committed to ensuring that knowledge from health and medical research is translated through commercialisation (e.g. by pharmaceutical or medical devices companies), improvements to policy, health service delivery and clinical practice.

Therefore, as a complement to other measures of research excellence (e.g. publication and citation rates), NHMRC considers industry-relevant skills, experience and achievements in its assessment of applicants' track records.

These measures recognise that applicants who have invested their research time on technology transfer, commercialisation or collaborating with industry, may have gained highly valuable expertise or outputs relevant to research translation. However, NHMRC acknowledges that these researchers will necessarily have had fewer opportunities to produce traditional academic research outputs (e.g. peer reviewed publications).

Therefore, peer reviewers should:

- Appropriately recognise applicants' industry-relevant experiences and results
- Allow for the time applicants have spent in commercialisation/industry for “*Relative to Opportunity*” considerations.

Who might have industry experience or be preparing for industry experience?

Many applicants to NHMRC may have had industry experiences of various kinds. Examples include, but are not limited to:

1. Researchers who have left academia to pursue a full time career in industry (e.g. in pharmaceutical, biotechnology or start-up companies). In such instances, outputs must be assessed ‘relative to opportunity’, as there may have been restrictions in producing traditional research outputs (such as peer reviewed publications), but highly valuable expertise gained or outputs produced relevant to research translation (such as patents or new clinical guidelines).
2. Academic researchers whose work has a possible commercial focus. These researchers might not have yet entered into commercial agreements with industry and have chosen to forego or delay publication in order to protect or extend their intellectual property (IP).
3. Academic researchers who have translated their discovery into a collaborative agreement with industry. The researcher may be collaborating with the company in further research and development; may have a licensing agreement; or may have licensed or assigned their IP to the company. A researcher may ultimately leave the academic institution and become Chief Executive Officer, Chief Scientific Officer, Chief Technology Officer, Scientific Advisory Board Member or consultant for a start-up or other company, based on their experience.
4. Academic researchers who are actively collaborating with companies, for example by providing expert research services for fees. Publications of such work might be precluded or delayed according to contract arrangements. The specialised nature of this research might also restrict publication to specialised journals only, as opposed to generalist journals.

Relevant industry outputs

Level of experience/ output	IP	Collaboration with an industry partner	Established a start- up company	Product to market	Clinical trials or regulatory activities	Industry participation
Advanced	<ul style="list-style-type: none"> • Patent granted: consider the type of patent and where it is granted. It can be more difficult to be granted a patent in, for example, the US or Europe than in Australia, depending on the patent prosecution and regulatory regime of the intended market • National phase entry and prosecution or specified country application 	<ul style="list-style-type: none"> • Executed a licensing agreement with an established company • Significant research contract with an industry partner • Long term consultancy with an industry partner 	<ul style="list-style-type: none"> • Achieved successful exit (public market flotation, merger or acquisition) • Raised significant (>\$10m) funding from venture capital or other commercial sources (not grant funding bodies) • Chief Scientific Officer, Executive or non-executive role on company boards 	<ul style="list-style-type: none"> • Produce sales • Successful regulator submission to US Food and Drug Administration (FDA), European Medicines Agency, TGA etc. • Medical device premarket submission e.g. FDA 510(k) approved 	<ul style="list-style-type: none"> • Phase II or Phase III underway or completed 	<ul style="list-style-type: none"> • Major advisory or consultancy roles with international companies
Intermediate	<ul style="list-style-type: none"> • Patent Cooperation Treaty (PCT) or ‘international application’ • Provisional patent 	<ul style="list-style-type: none"> • Established a formal arrangement such as a consultancy or research contract and actively collaborating 	<ul style="list-style-type: none"> • Incorporated an entity and established a board • Has raised moderate (>\$1m) funding from commercial sources or government schemes that required industry co-participation (e.g. ARC Linkage, 	<ul style="list-style-type: none"> • Generated regulatory standard data set • Successful regulatory submission to Therapeutic Goods Administration or European Conformity (CE) marking • Medical device: 	<ul style="list-style-type: none"> • Phase I underway or completed • Protocol development • Patient recruitment 	<ul style="list-style-type: none"> • Advisory or consultancy role with a national company

			NHMRC Development Grant)	applications for pre-market approval		
Preliminary	<ul style="list-style-type: none"> • IP generated • Patent application lodged • Invention lodged with Disclosure/s with Technology Transfer/Commercialisation Office 	<ul style="list-style-type: none"> • Approached and in discussion with an industry partner under a non-disclosure agreement. No other formal contractual arrangements. 	<ul style="list-style-type: none"> • Negotiated licence to IP from the academic institution 	<ul style="list-style-type: none"> • Developed pre-good manufacturing practice (GMP) prototype and strong supporting data • Established quality systems 	<ul style="list-style-type: none"> • Drug candidate selected or Investigative New Drug application filed • Preclinical testing 	